{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:58:29Z","timestamp":1776448709594,"version":"3.51.2"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.004","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:40:54Z","timestamp":1773952854000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Yuval","family":"Elkun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murilo","family":"De Almeida Luz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh K.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2026.02.004_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","article-title":"2022 update on prostate cancer epidemiology and risk factors \u2013 a systematic review","volume":"84","author":"Bergengren","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1590\/s1677-5538.ibju.2020.1063","article-title":"Pelvic lymph node dissection in high-risk prostate cancer","volume":"48","author":"Haiquel","year":"2022","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib3","first-page":"680","article-title":"Pelvic lymph node dissection in prostate and bladder cancers","volume":"74","author":"Rocco","year":"2022","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.ucl.2026.02.004_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2007.07.035","article-title":"The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study","volume":"53","author":"Mattei","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ucl.2017.07.007","article-title":"Extent of lymphadenectomy at time of prostatectomy: an evidence-based approach","volume":"44","author":"Vollstedt","year":"2017","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.ucl.2026.02.004_bib6","doi-asserted-by":"crossref","first-page":"365.e1","DOI":"10.1016\/j.urolonc.2018.05.019","article-title":"Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection","volume":"36","author":"Preisser","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib7","first-page":"41","article-title":"Value of and indication for pelvic lymph node dissection in the staging of prostate cancer","volume":"7","author":"Middleton","year":"1988","journal-title":"NCI Monogr"},{"key":"10.1016\/j.ucl.2026.02.004_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.eururo.2006.01.043","article-title":"Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy","volume":"49","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1442-2042.1998.tb00388.x","article-title":"Incidence of lymph node metastasis and its impact on long-term prognosis in clinically localized prostate cancer","volume":"5","author":"Arai","year":"1998","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12957-024-03344-2","article-title":"The role and controversy of pelvic lymph node dissection in prostate cancer treatment: a focused review","volume":"22","author":"Dong","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guidelines, part II: principles of active surveillance, principles of surgery, and Follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib14","unstructured":"National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2025. 2025. Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1459."},{"key":"10.1016\/j.ucl.2026.02.004_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(17)35410-1","article-title":"The use of prostate specific antigen, clinical stage, and gleason score to predict pathological stage in men with localized prostate cancer","volume":"150","author":"Partin","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.eururo.2017.03.049","article-title":"Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102364","article-title":"Integrating genomic classifiers and nonsuspicious magnetic resonance imaging findings in predictive modelling for lymph node metastasis in patients with localized prostate cancer","volume":"23","author":"Wagaskar","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ucl.2026.02.004_bib19","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1097\/01.ju.0000091805.98960.13","article-title":"A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer","volume":"170","author":"Cagiannos","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer - 2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/21681805.2017.1332680","article-title":"Comparison between briganti, partin, and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis","volume":"51","author":"Cimino","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.euo.2023.05.003","volume":"6","author":"Gandaglia","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib23","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/cncr.22034","article-title":"Current status of lymph node-positive prostate cancer: incidence and predictors of outcome","volume":"107","author":"Swanson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2026.02.004_bib24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM193409132111101","article-title":"Autopsy findings in 100 cases of prostate cancer","volume":"211","author":"Mintz","year":"1934","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2026.02.004_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib26","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/j.clgc.2017.10.003","article-title":"Rate and extent of pelvic lymph node dissection in the US prostate cancer patients treated with radical prostatectomy","volume":"16","author":"Nocera","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ucl.2026.02.004_bib27","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0022-5347(05)65177-4","article-title":"Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis","volume":"167","author":"Heidenreich","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib28","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0022-5347(05)64670-8","article-title":"Is a limited lymph node dissection an adequate staging procedure for prostate cancer?","volume":"168","author":"Bader","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for Intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib30","doi-asserted-by":"crossref","first-page":"310.e1","DOI":"10.1016\/j.urolonc.2018.03.004","article-title":"Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease","volume":"36","author":"Badani","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2014.05.011","article-title":"More extensive pelvic lymph node dissection improves survival in patients with node-Positive prostate cancer","volume":"67","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.euo.2021.02.001","article-title":"Impact of pelvic lymph node dissection and its extent on perioperative morbidity in patients undergoing radical prostatectomy for prostate cancer: a comprehensive systematic review and meta-analysis","volume":"4","author":"Cacciamani","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib33","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","article-title":"Complication and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer","volume":"50","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib34","first-page":"103","article-title":"Pelvic lymph node dissection in prostate cancer staging: evaluation of morbidity and oncological outcomes","volume":"119","author":"Van Huele","year":"2019","journal-title":"Acta Chir Belg"},{"key":"10.1016\/j.ucl.2026.02.004_bib35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/pros.24085","article-title":"Influence of pelvic lymph node dissection and node-Positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer","volume":"81","author":"Washington","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2026.02.004_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.prnil.2024.07.002","article-title":"Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with High- or very high-risk prostate cancer: a multi-institutional study","volume":"12","author":"Washino","year":"2024","journal-title":"Prostate Int"},{"key":"10.1016\/j.ucl.2026.02.004_bib37","article-title":"Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ucl.2026.02.004_bib38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1245\/s10434-017-5822-6","article-title":"Extended versus standard pelvic lymph node dissection in radical prostatectomy on oncological and functional outcomes: a systematic review and meta-analysis","volume":"24","author":"Choo","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/pros.23491","article-title":"Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion","volume":"78","author":"Preisser","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2026.02.004_bib40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bju.15034","article-title":"Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion","volume":"125","author":"Sood","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2026.02.004_bib41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JU.0000000000004587","article-title":"Pelvic lymph node dissection in prostate cancer: is it really necessary? A multicentric longitudinal study assessing oncological outcomes in patients with prostate cancer undergoing pelvic lymph node dissection vs radical prostatectomy only","volume":"214","author":"Furrer","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib42","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/pros.24884","article-title":"Impact of pelvic lymph node dissection on early oncological outcomes in intermediate-risk prostate cancer patients with node-negative PSMA PET","volume":"85","author":"Esen","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.ucl.2026.02.004_bib43","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41391-024-00930-z","article-title":"Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer","volume":"28","author":"Incesu","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ucl.2026.02.004_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.004_bib45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/JU.0000000000000290","article-title":"A 17-Gene genomic prostate score as a predictor of adverse pathology in men on active surveillance","volume":"202","author":"Kornberg","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41585-024-00912-9","article-title":"From foes to friends: rethinking the role of lymph nodes in prostate cancer","volume":"21","author":"Gupta","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2026.02.004_bib48","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.241828","article-title":"The lymph node at a glance - how spatial organization optimizes the immune response","volume":"133","author":"Grant","year":"2020","journal-title":"J Cell Sci"},{"key":"10.1016\/j.ucl.2026.02.004_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ucl.2026.02.004_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ucl.2026.02.004_bib51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-Checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"issue":"7_Supplement","key":"10.1016\/j.ucl.2026.02.004_bib52","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT023","article-title":"Abstract CT023: prostate cancer in situ autovaccination with the intratumoral viral mimic Poly-ICLC: making a cold tumor hot","volume":"84","author":"Nair","year":"2024","journal-title":"Cancer Res"},{"issue":"13_Supplement","key":"10.1016\/j.ucl.2026.02.004_bib53","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT096","article-title":"Abstract CT096: phase I study of in situ autologous vaccination for prostate cancer in a neo-adjuvant setting","volume":"79","author":"Nair","year":"2024","journal-title":"Cancer Res"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:21:32Z","timestamp":1776446492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000042"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.004","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}